Literature DB >> 12721914

The elimination of indigenous measles transmission in England and Wales.

Mary E Ramsay1, Li Jin, Joanne White, Pam Litton, Bernard Cohen, David Brown.   

Abstract

Following a school-based measles-rubella vaccination campaign in November 1994, enhanced surveillance of measles, including IgM antibody testing of oral fluid from clinically diagnosed case-patients, was introduced in England and Wales. Between 1995 and 2001, 665 cases of measles were confirmed, including 371 (56%) confirmed only by IgM detection in oral fluid. Two hundred thirty-nine cases (36%) were sporadic and 426 (64%) were associated with 61 clusters. Fifty-four (23%) of the 239 sporadic cases and 26 (43%) of the 61 clusters were associated with a probable or possible importation of infection from overseas, and a wide variety of genotypes were identified in each calendar year. The effective reproduction number for measles over the period was estimated to be below 0.7. These data suggest that most measles in the UK is acquired following limited transmission from an imported infection, and they confirm that measles elimination has been achieved and sustained over this period.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721914     DOI: 10.1086/368024

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  An assessment of measles vaccine effectiveness, Australia, 2006-2012.

Authors:  Alexis Pillsbury; Helen Quinn
Journal:  Western Pac Surveill Response J       Date:  2015-07-09

2.  Impact of adverse publicity on MMR vaccine uptake: a population based analysis of vaccine uptake records for one million children, born 1987-2004.

Authors:  V Friederichs; J C Cameron; C Robertson
Journal:  Arch Dis Child       Date:  2006-04-25       Impact factor: 3.791

Review 3.  Measles in the United Kingdom: can we eradicate it by 2010?

Authors:  Perviz Asaria; Eithne MacMahon
Journal:  BMJ       Date:  2006-10-28

4.  Elimination of endemic measles transmission in Australia.

Authors:  Anita E Heywood; Heather F Gidding; Michaela A Riddell; Peter B McIntyre; C Raina MacIntyre; Heath A Kelly
Journal:  Bull World Health Organ       Date:  2009-01       Impact factor: 9.408

5.  Towards elimination: measles susceptibility in Australia and 17 European countries.

Authors:  Nick Andrews; Annedore Tischer; Annette Siedler; Richard G Pebody; Christopher Barbara; Suzanne Cotter; Arnis Duks; Nina Gacheva; Kriz Bohumir; Kari Johansen; Joel Mossong; Fernando de Ory; Katarina Prosenc; Margareta Sláciková; Heidi Theeten; Marios Zarvou; Adriana Pistol; Kalman Bartha; Dani Cohen; Jo Backhouse; Algirdas Griskevicius
Journal:  Bull World Health Organ       Date:  2008-03       Impact factor: 9.408

Review 6.  Review of the temporal and geographical distribution of measles virus genotypes in the prevaccine and postvaccine eras.

Authors:  Michaela A Riddell; Jennifer S Rota; Paul A Rota
Journal:  Virol J       Date:  2005-11-22       Impact factor: 4.099

7.  Estimating the measles effective reproduction number in Australia from routine notification data.

Authors:  May Chiew; Heather F Gidding; Aditi Dey; James Wood; Nicolee Martin; Stephanie Davis; Peter McIntyre
Journal:  Bull World Health Organ       Date:  2013-12-09       Impact factor: 9.408

8.  Seasonal infectious disease epidemiology.

Authors:  Nicholas C Grassly; Christophe Fraser
Journal:  Proc Biol Sci       Date:  2006-10-07       Impact factor: 5.349

9.  The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990-2002.

Authors:  C Miller; N Andrews; M Rush; H Munro; L Jin; E Miller
Journal:  Arch Dis Child       Date:  2004-12       Impact factor: 3.791

10.  Identifying infections with respiratory syncytial virus by using specific immunoglobulin G (IgG) and IgA enzyme-linked immunosorbent assays with oral-fluid samples.

Authors:  Emelda A Okiro; Charles Sande; Martin Mutunga; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  J Clin Microbiol       Date:  2008-02-27       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.